Chronic Obstructive Pulmonary Disease Clinical Trial
Official title:
The Role of Endorphins in the Perception of Dyspnea With Resistive Loading in Patients With COPD
Endorphins are released in response to breathing difficulty and can modify the perception of breathlessness. In this randomized placebo-controlled trial, resistive breathing loads are used to provoke breathlessness in patients with chronic obstructive pulmonary disease. The hypothesis of the study is that intravenous (IV) administration of naloxone, a medication which blocks endorphin activity, will increase the perception of breathlessness experienced by patients while breathing through a resistance device, compared with IV administration of normal saline.
Study Design:
The study is a randomized, double-blind, placebo-controlled investigation comparing the
intravenous administration of:
- normal saline, considered a placebo, is expected to have no effect on patient ratings
of dyspnea.
- naloxone, an opioid receptor antagonist with penetration into the central nervous
system and blocks the effect of beta-endorphins, is expected to increase ratings of
dyspnea in patients with COPD.
Dyspnea will be induced by resistive load breathing for a minimum of 10 minutes.
Subjects:
Twenty subjects with COPD will be recruited from the outpatient clinic at the
Dartmouth-Hitchcock Medical Center.
Procedures:
There are three visits each 2 - 3 days apart.
Visit 1
The purposes of Visit 1 are:
- to ensure that patients meet inclusion and exclusion criteria
- to collect baseline data
- to familiarize each patient with the study protocol
- to practice breathing through the resistive load system
Visit 2 (2 - 3 days after Visit 1)
Patients will perform pulmonary function tests and then inhale 2 puffs (180 mcg) of
albuterol metered-dose inhaler (MDI) in order to provide standardized bronchodilatation
prior to resistance breathing. Thirty minutes later, pulmonary function tests will be
repeated to measure the response.
Next, patients will be randomized to one of two blinded study medications.
1. normal saline (25 ml volume) intravenous infusion given 5 minutes before resistive
breathing
2. naloxone (10mg in 25 ml total volume) intravenous push given 5 minutes prior to
resistive breathing
An 18-20 gauge catheter will be inserted into an arm vein to be used for drawing blood and
for administration of either normal saline or naloxone. In a seated position, the patient
will breathe quietly through the mouth piece without any resistance. After 5 minutes, 10 ml
of venous blood will be removed for measurement of baseline plasma beta-endorphin
immunoreactivity. Then, the physician will give the normal saline or naloxone solution
intravenously through tubing connected to the catheter. Five minutes after the infusion has
been given, the resistance load (obtained at Visit 1) will be added to the inspiratory side
of a two-way valve. The patient will be instructed to continue breathing through the
resistance "for as long as possible." At one minute intervals, the patient will be asked to
place a mark on a vertical visual analog scale (VAS) in order to rate separately the
intensity and the unpleasantness of dyspnea. When the patient is no longer able to breathe
through the resistance system, the patient will be asked to make final ratings of the
intensity and the unpleasantness of dyspnea. Thereafter, resistance breathing will be
stopped, and the mouthpiece will be removed from the patient. Next, 10ml of venous blood
will be removed for measurement of the plasma beta-endorphin immunoreactivity. A third 10 ml
aliquot of venous blood will be taken at 30 minutes after completion of the resistive
breathing session.
During the 5 minutes of breathing normally at rest and during the resistance breathing, the
following non-invasive measurements will be made: inspiratory mouth pressure (Pm); expired
gas will be analyzed breath-by-breath for minute ventilation (VE), oxygen consumption (VO2),
and carbon dioxide production (VCO2) using a metabolic measurement system (MedGraphics);
oxygen saturation will be recorded using a pulse oximeter; and end-tidal partial pressure of
CO2.
Visit 3
At Visit 3, the same procedures will be used as described for Visit 2, except that the
patient will be randomized to the alternative blinded study medication that he/she did not
receive at Visit 2.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|